Glimzab MP 1mg/500mg/15mg Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg. This formulation is designed for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on monotherapy or dual therapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin action in adipose tissue, muscle, and the liver. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects and improved patient compliance. Glimzab MP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of bladder cancer. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy should be prescribed and adjusted based on individual patient response and tolerability.